Why Insulin Never Reaches the Liver

Send us Fan Mail The liver is the only organ in the body that can release stored glucose to prevent low blood sugar. So why has injected insulin never been able to reach it? In this clip from our episode “Finding a Solution for GLP-1 Side Effects”, host David E. Williams and Bob Geho, Founder and CEO of Diasome, break down the biological gap at the heart of diabetes treatment and how a father's decades of research into liver-targeted insulin delivery became the founding idea behind Diasome. **🎙️⚕️ABOUT BOB GEHO** Bob Geho is the Chief Executive Officer of Diasome Pharmaceuticals, a clinical-stage biopharmaceutical company developing portal-hepatic -targeted therapies designed to act at the source of metabolic regulation. Under his leadership, Diasome is advancing its proprietary Hepatocyte-Directed Vesicle (HDV) platform, which targets liver hepatocytes and the portal hepatic region, where metabolic control is centered. The company's lead clinical program, HDV-Insulin, applies this approach to insulin therapy — grounded in the principle that therapies working with the body's natural physiology may produce meaningfully better outcomes. The HDV platform is also being explored across GLP-1 and serotonin programs. Bob's work in hepatic-directed drug delivery spans more than three decades, including helping lead the first successful human clinical study of liver-targeted insulin in Type 1 diabetes patients. He co-founded Diasome in 2004 and has since guided the company through multiple rounds of financing and into clinical development. He also co-founded SDG, Inc., a Cleveland-based holding company that has supported the creation of multiple life sciences startups and strategic partnerships. He holds an MBA from Case Western Reserve University. **🎙️⚕️ABOUT HEALTH BIZ PODCAST** HealthBiz is a CareTalk podcast that delivers in-depth interviews on healthcare business, technology, and policy with entrepreneurs and CEOs. Host David E. Williams — president of the healthcare strategy consulting boutique Health Business Group — is also a board member, investor in private healthcare companies, and author of the Health Business Blog. Known for his strategic insights and sharp humor, David offers a refreshing break from the usual healthcare industry BS. **Need a Strategy Partner?** For over 20 years, Health Business Group has helped healthcare software companies, tech-enabled services businesses, life sciences companies, and payers make smarter strategic decisions. Led by podcast host David Williams, the firm advises clients on sharpening AI positioning, entering new segments, and building commercial strategies for value-based care. See examples of our work at healthbusinessgroup.com/ **GET IN TOUCH** Follow CareTalk on LinkedIn Become a CareTalk sponsor Guest appearance requests Visit us on the web Support the show **⚙️CareTalk:  Healthcare. Unfiltered. is produced by** Grippi Media Digital Marketing Consulting.